Although this study confirmed the presence of previously known mutations in GI tumors, one of the interesting findings was the presence of BRCA2 mutations in 25% of the tested pancreatic adenocarcinoma samples allowing for tailored therapy using platinum‐based or mitomycin‐based agents for these patients. Here, BRCA2 is linked to digestive system neoplasm.